MUMBAI, India, March 13 -- Intellectual Property India has published a patent application (202611009518 A) filed by Swami Vivekananda Subharti University, Meerut, Uttar Pradesh, on Jan. 30, for 'a composition, a microencapsulation system and a method for ulcer-selective drug release using a ph-responsive and redox-activated piperazine-chalcone hybrid.'
Inventor(s) include Dr. Manish Pathak.
The application for the patent was published on March 13, under issue no. 11/2026.
According to the abstract released by the Intellectual Property India: "The present invention relates to a dual-trigger microcapsule system for targeted gastric-ulcer therapy, incorporating a Piperazine-Chalcone hybrid molecule within a multi-layered, stimuli-responsive architecture. The hybrid compound exhibits dual pharmacological action, providing anti-Helicobacter pylori activity and anti-inflammatory mucosal protection. The microcapsule comprises a pH-responsive outer layer that remains intact in strongly acidic gastric fluid but relaxes at the moderately elevated pH characteristic of ulcer lesions. Beneath this layer, a redox-sensitive polymer membrane selectively degrades in the presence of elevated reactive oxygen species generated in inflamed ulcer tissue, enabling site-specific release of the hybrid molecule. Optional mucoadhesive surface groups promote retention on mucin-depleted ulcer surfaces, enhancing localized therapeutic exposure. The system ensures protection of the hybrid from premature degradation, minimizes systemic irritation, and provides controlled release precisely at diseased sites. This invention offers a cost-effective, stable, and efficient approach for improving ulcer healing and reducing multidrug treatment burdens."
Disclaimer: Curated by HT Syndication.
